Department of Breast Surgery, the Second Hospital of Shandong University, Jinan, Shandong Province, People's Republic of China.
Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.
Oncologist. 2017 Dec;22(12):1431-1443. doi: 10.1634/theoncologist.2017-0148. Epub 2017 Sep 14.
Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk. Body mass index (BMI) and waist/hip ratio (WHR) have demonstrated different effects on breast cancer risk in relation to estrogen receptor (ER) status, but the results have been inconsistent. Furthermore, the situation in Chinese women remains unclear.
We conducted a case-control study including 1,439 breast cancer cases in Northern and Eastern China. Both ER and progesterone receptor (PR) statuses were available for 1,316 cases. Associations between body size-related factors and breast cancer risk defined by receptor status were assessed by multiple polytomous unconditional logistic regression analysis.
Body mass index and WHR were positively associated with overall breast cancer risk. Body mass index was positively associated with both ER+/PR positive (PR+) and ER negative (ER-)/PR negative(PR-) subtype risks, although only significantly for ER+/PR+ subtype. Waist-hip ratio was only positively correlated with ER-/PR- subtype risk, although independent of BMI. Body mass index was positively associated with risk of ER+/PR+ and ER-/PR- subtypes in premenopausal women, whereas WHR was inversely correlated with ER+/PR- and positively with ER-/PR- subtype risks. Among postmenopausal women, WHR >0.85 was associated with increased risk of ER-/PR- subtype.
Both general and central obesity contribute to breast cancer risk, with different effects on specific subtypes. General obesity, indicated by BMI, is more strongly associated with ER+/PR+ subtype, especially among premenopausal women, whereas central obesity, indicated by WHR, is more specific for ER-/PR- subtype, independent of menopausal status. These results suggest that different chemoprevention strategies may be appropriate in selected individuals.
The results of this study suggest that general and central obesity may play different roles in different breast cancer subtypes, supporting the hypothesis that obesity affects breast carcinogenesis via complex molecular interconnections, beyond the impact of estrogens. The results also imply that different chemoprevention strategies may be appropriate for selected individuals, highlighting the need to be particularly aware of women with a high waist/hip ratio but normal body mass index. Given the lack of any proven pharmacologic intervention for estrogen receptor negative breast cancer, stricter weight-control measures may be advised in these individuals.
肥胖是雌激素受体(ER)阳性(ER+)乳腺癌风险药物干预的一个考虑因素。体重指数(BMI)和腰臀比(WHR)已证明在与雌激素受体(ER)状态相关的乳腺癌风险方面具有不同的影响,但结果不一致。此外,中国女性的情况尚不清楚。
我们在中国北方和东部进行了一项病例对照研究,包括 1439 例乳腺癌病例。1316 例病例均有 ER 和孕激素受体(PR)状态。通过多分类非条件逻辑回归分析评估与体型相关因素与受体状态定义的乳腺癌风险之间的关联。
BMI 和 WHR 与总体乳腺癌风险呈正相关。BMI 与 ER+/PR+(PR+)和 ER 阴性(ER-)/PR 阴性(PR-)亚型风险均呈正相关,尽管仅与 ER+/PR+ 亚型显著相关。WHR 仅与 ER-/PR- 亚型风险呈正相关,而与 BMI 无关。BMI 与绝经前妇女的 ER+/PR+和 ER-/PR- 亚型风险呈正相关,而 WHR 与 ER+/PR-和 ER-/PR- 亚型风险呈负相关。绝经后妇女中,WHR>0.85 与 ER-/PR- 亚型风险增加相关。
全身性和中心性肥胖均与乳腺癌风险相关,对特定亚型的影响不同。BMI 表示的全身性肥胖与 ER+/PR+ 亚型的相关性更强,尤其是在绝经前妇女中,而 WHR 表示的中心性肥胖与 ER-/PR- 亚型更为特异,与绝经状态无关。这些结果表明,在选定的个体中,可能需要采用不同的化学预防策略。
本研究结果表明,全身性和中心性肥胖可能在不同的乳腺癌亚型中发挥不同的作用,支持肥胖通过复杂的分子相互联系影响乳腺癌发生的假说,而不仅仅是通过雌激素的影响。结果还表明,针对特定个体,可能需要采用不同的化学预防策略,突出了需要特别注意腰臀比高但 BMI 正常的女性。由于目前尚无针对雌激素受体阴性乳腺癌的药物干预措施,因此这些个体可能需要更严格的体重控制措施。